ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20261106078 Date: November 06, 2026

To, **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India **SCRIP CODE: 543275**	To, **National Stock Exchange of India Limited** 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India **SYMBOL: ANURAS**

Dear Sir/Madam,

Subject: Investor Presentation- Q2 of FY27

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the 'Investor Presentation' in respect of the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026, of Anupam Rasayan India Limited (the "*Company*").

The Investor Presentation will also be hosted on the website of the Company at www.anupamrasayan.com.

We request you to kindly note the same and take into your records.

Thanking you,

Yours Faithfully,

For Anupam Rasayan India Limited

ASHISH GUPTA
Digitally signed by ASHISH GUPTA
Date: 2026.11.06 16:02:29 +05'30'

Ashish Gupta
Company Secretary & Compliance Officer

Encl.: As above

Registered Office:
Office Nos. 1101 to 1107, 11th Floor, Icon Rio,
Behind Icon Business Centre, Dumas Road,
Surat-395007, Gujarat, India.

Tel. : **+91-261-2398991-95**
Fax : **+91-261-2398996**
E-mail : **office@anupamrasayan.com**
Website : **www.anupamrasayan.com**
CIN - L24231GJ2003PLC042988

ANUPAM RASAYAN INDIA LTD.

Anupam Rasayan India Limited







Q2 & H1FY27

Investor Presentation

Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Anupam Rasayan India Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe to any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over-runs on contracts, our ability to manage our international operations, government policies and actions, regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

01

Quarterly & Half Yearly Highlights



Quarterly **Financial Highlights**

Consolidated
Total Revenue

₹821 Cr

Q-o-Q growth of **23%**

Consolidated EBITDA

₹202 Cr

Q-o-Q growth of **16%**

Consolidated
Profit After Tax

₹65 Cr

Q-o-Q growth of **27%**

Standalone
Total Revenue

₹413 Cr

Q-o-Q growth of **23%**

Standalone
EBITDA

₹141 Cr

Q-o-Q growth of **22%**

Standalone
Profit After Tax

₹46 Cr

Q-o-Q growth of **43%**



Half-Yearly **Financial Highlights**

Consolidated
Total Revenue

₹1,489 Cr

Y-o-Y growth of **21%**

Consolidated EBITDA

₹377 Cr

Y-o-Y growth of **38%**

Consolidated
Profit After Tax

₹116 Cr

Y-o-Y growth of **10%**

Standalone
Total Revenue

₹748 Cr

Y-o-Y growth of **2%***
excluding one-off sale

Standalone
EBITDA

₹257 Cr

Y-o-Y growth of **19%**

Standalone
Profit After Tax

₹78 Cr

Y-o-Y growth of **9%**



** The decline is attributable to a higher base in Q2 FY26, when one-off sales accounted for 180 Cr of revenue.*

Key Highlights for H1FY27

Operational Highlights

- Delivered the highest-ever quarterly consolidated revenue of Rs 812 Cr, registering 10% YoY growth
- Consolidated EBITDA grew by 41% YoY to Rs 202 Cr, with margins improving to 25% from 19%, driven by a higher contribution from high-margin Performance Materials and Pharmaceutical products
- Generated operating cash flow of ₹328 crore as of September 2026, compared to ₹334 crore as of March 2026, supported by stronger profitability and improved working capital management.

Bliss GVS Acquisition

- Acquired 50.07% controlling stake in Bliss GVS Pharma Limited, with the transaction completed on 28th September 2026.
- Strategic Entry into Finished Dosage Formulations (FDF), complementing existing capabilities in pharmaceutical intermediates and custom synthesis.
- Strengthens Global Pharmaceutical Presence through Bliss GVS's established product portfolio, manufacturing capabilities and international market reach.

Other Developments

- Signed a six-year long-term supply contract with a leading US-based global specialty metal manufacturer, marking entry into a new segment within the geological resources sector.
- Strengthened strategic investment in Tanfac Industries through participation in a preferential issue of equity shares.
- Received a Crisil ESG rating of 62 “Strong” and a Crisil Core ESG rating of 63 “Strong”, improved from 54 “Adequate” in the previous year.

Managing Director's Message

Mr. Anand S Desai
MANAGING DIRECTOR



"H1 FY27 was marked by steady progress across our strategic priorities, expansion into new end markets and continued strengthening of our business portfolio. We are pleased to have achieved our highest-ever quarterly consolidated revenue during Q2 FY27, reflecting the resilience of our diversified business and the progress made across key segments.

Our focus continue to remain on building a globally integrated specialty chemicals platform by deepening relationships with existing customers, expanding into new applications and strengthening our capabilities across Pharmaceuticals, Performance Materials and other specialised segments.

During the quarter, we signed a six-year long-term supply agreement with a US-based speciality metal manufacturer. This marks an important step towards establishing our presence in the geological resources sector, diversifying our customer base and building a long-term strategic partnership with a global customer.

We also successfully completed the acquisition of a 50.07% stake in Bliss GVS Pharma, securing a controlling interest and marking a significant step in our vision of building a diversified pharmaceutical platform. The acquisition brings complementary capabilities in finished dosage formulations and provides opportunities to strengthen our presence across the pharmaceutical value chain, leverage operational and commercial synergies and expand our growth opportunities.

Going forward, we remain focused on disciplined execution, optimal utilization of our capital employed, successful integration of our strategic investments and continuous enhancement of our manufacturing and technological capabilities. We believe these initiatives will strengthen our business resilience, support sustainable growth and create long-term value for all stakeholders."

Consolidated Q2 & H1FY27 Profit & Loss Statement

Particulars (Rs. Cr)	Q2FY27	Q2FY26	YoY	H1FY27	H1FY26	YoY
Revenue from Operations	806	731*		1,461	1,217	
Other Income	15	8		28	13	
Total Income	**821**	**739**	**11%**	**1,489**	**1,230**	**21%**
Cost of materials consumed	398	474		682	718	
Employee Expenses	68	17		133	38	
Other Expenses	144	104		287	201	
EBITDA	**202**	**144**	**41%**	**377**	**273**	**38%**
EBITDA Margin (%)	**25%**	**19%**		**25%**	**22%**	
Depreciation	57	32		113	63	
EBIT	**146**	**112**		**265**	**210**	
Finance Cost	56	36		105	72	
Profit before Tax	**89**	**76**		**159**	**138**	
Tax	24	18		43	33	
Profit After Tax	**65**	**57**	**14%**	**116**	**106**	**10%**
PAT Margin (%)	**8%**	**8%**		**8%**	**9%**	
EPS	6.81	3.93		10.21	7.03	
Cash Profit	**122**	**89**	**37%**	**229**	**168**	**36%**

**Includes one off sales of INR 180 crore.*

Consolidated Balance Sheet

Assets (Rs. Cr)	Sept-26	Mar-26
Non Current Asset	**6,214**	**4,285**
Net Fixed Asset	3,774	3,094
Financial Assets	208	153
Other Non-current assets	2,232	1,038
Current Asset	**5,181**	**3,728**
Inventories	2,089	1,775
Trade Receivables	1,582	959
Cash and Cash Equivalent	764	394
Other current assets	746	600
Total	**11,395**	**8,013**

Equity & Liabilities (Rs. Cr)	Sept-26	Mar-26
Shareholders' Funds	**5,048**	**3,334**
Non Controlling Interest	2,148	1,296
Non Current Liabilities	**1,144**	**767**
Long-Term Borrowings	853	511
Lease Liability	62	49
Other long-term liabilities	229	208
Current Liabilities	**3,054**	**2,615**
Short-term Borrowings	1,605	1,304
Lease Liability	13	4
Trade Payables	1,114	946
Other current liabilities	323	362
Total Liabilities	**11,395**	**8,013**

Note: Bliss GVS Pharma Limited has contributed to revenue from September 28, 2026, following the acquisition of a 50.07% stake. However, the consolidated Balance Sheet includes its financials in full.

Consolidated Cash Flow Statement

Particulars (Rs. Cr)	Sept-26	Mar-26
Net Profit Before Tax	**159**	**254**
Adjustments for: Non -Cash Items / Other Investment or Financial Items	249	296
Operating profit before working capital changes	**408**	**550**
Changes in working capital	-80	-171
Cash generated from Operations	**328**	**379**
Direct taxes paid (net of refund)	-25	-45
Net Cash from Operating Activities	**303**	**334**
Net Cash from Investing Activities	**-2,318**	**-820**
Net Cash from Financing Activities	**2,228**	**621**
Net Decrease in Cash and Cash equivalents	**214**	**135**
Add: Cash & Cash equivalents at the beginning of the period	420	243
Cash & Cash equivalents at the end of the period	**634**	**378**
Fixed Deposit Investments	130	16
Cash & Cash equivalents including Fixed Deposit Investments	**764**	**394**

Note: Bliss GVS Pharma Limited has contributed to revenue from September 28, 2026, following the acquisition of a 50.07% stake. However, the consolidated Cashflow includes its financials in full.

02

Business Overview



Anupam Group: Corporate Structure

ANUPAM RASAYAN INDIA LIMITED

ANUPAM RASAYAN INDIA
Custom Manufacturing Platform

Standalone

Rs.748 Cr	Rs. 1,676 Cr
H1 FY27 REVENUE	FY26 REVENUE

29,852 MT
CAPACITY

TANFAC INDUSTRIES
Fluorochemicals Platform

Subsidiary

Rs. 422 Cr	Rs. 711 Cr
H1 FY27 REVENUE	FY26 REVENUE

1.35L MT
CAPACITY

JAYHAWK FINE CHEMICALS
Advanced CDMO Platform

Wholly-Owned Subsidiary

Rs. 298 Cr*	Rs. 722 Cr*
H1 FY27 REVENUE	FY26 REVENUE

36,000 MT
CAPACITY

BLISS GVS PHARMA
Finished Formulations Platform

Subsidiary

Rs. 617 Cr	Rs. 927 Cr
H1 FY27 REVENUE	FY26 REVENUE

4,822 Mn units
CAPACITY

Rs 4,000+Crores
Group Proforma FY26 Revenue

2,00,000+MT
Specialty Chemicals Capacity

4,800+Mn Units
Pharmaceutical Formulation Capacity

**USD to INR conversion at ₹95/US$*

Leading **Custom Synthesis Manufacturer**

4 Decades
Strong track record

Backward Integrated
Reliable supply chain for Customers

14
State of the Art Manufacturing Plants

2,00,000+
Total Manufacturing Capacity

4,800+Mn Units
Pharmaceutical Formulation Capacity

200+ Clients
Including 55+ MNCs

175+
Strong R&D Team of Professionals

Global Certifications
US FDA, EU GMP, FDA Russia, WHO GMP, TGA Australia

3,500+
Committed Employees

Fast growing Specialty Chemical Manufacturer with focus on Custom Synthesis.

Longstanding relationships with leading MNCs

Leveraging deep expertise across complex chemistries

Building platforms across business verticals of Agro, Personal Care, Pharma and Performance Materials

On track to achieve **best-in-class ESG standards by 2028**

Energy net zero by 2028 on Scope 1+2 emissions

Note: Numbers on Consolidated basis

Evolution of Anupam

PHASE I-INCEPTION

1984
Formed partnership firm "Anupam Rasayan"

2006
Started supplying Anti-Bacterial products for German MNC

2010
Started supplying to Syngenta

2014
Commercialized large scale manufacturing site - Unit 4

2016
Awarded 'Green Innovation Award' by Corning Reactor Technology

PHASE II- BUILD UP

2017
Started supplying to Sumitomo Japan

2019
Commercialized 2 more manufacturing sites – Unit 5 & 6

2020
Received DSIR registration for R&D Centre

2021
- Started supplying to Adama
- Listed on NSE and BSE
- Commissioned Solar Power Plant of 12.5MW at Bharuch

PHASE III- THE ACCELERATION

2022
- Acquired controlling stake in **Tanfac Industries Ltd**.


2023
- Raised ₹500 Cr. through QIP
- Commissioned Solar Power Plant of 5.4MW at Bharuch

2024
- Raised ₹550 Cr. through Preferential Issue
- Commissioned Hybrid Power Plant of 9.6MW

2026
- Acquired U.S. based **Jayhawk Fine Chemicals Corporation**
- Acquired Equity shares worth Rs. 61 Cr in Tanfac Industries through a preferential issue.
- Acquired controlling stake in **Bliss GVS Pharma Limited**

Consolidated Revenue:

(Rs in Crs)



Diversified **Product Portfolio serving 200+ Clients**

01

LIFE SCIENCE RELATED SPECIALITY CHEMICALS

a. Agrochemicals (including Crop Protection)
Manufacturing agrochem intermediates and agrochem active ingredients (insecticides, fungicides and herbicides)

b. Personal Care
Manufacturing anti-bacterial and ultraviolet protection intermediates and ingredient

c. Pharmaceuticals
Developing intermediates and 'key starting materials' for APIs, material sciences and surface chemistry

02

PERFORMANCE MATERIALS

a. Polymer
Manufacturing specialty monomers, ionomers, and oligomers, including high-performance materials for defense, aerospace, and semiconductor applications, utilizing anhydrous hydrogen fluoride across both fluorinated and non-fluorinated chemistries

b. Electronic Chemicals
Manufacturing niche molecules for the electronics ecosystem, offering high-quality, low metal content advanced materials used in display chemicals, heat transfer fluids, and AR/VR applications, along with solutions for frontend and backend semiconductor processes, including organic and inorganic fluoride-based battery chemicals.

03

OTHER FLUORINATED PRODUCTS (TANFAC)

a. Portfolio of fluorine-based chemicals, led by Hydrofluoric Acid and its derivatives, alongside Aluminium Fluoride, Potassium Fluorides, Boron Trifluoride Complexes and specialty fluorinated products.

b. Products serve critical applications across agrochemicals, pharmaceuticals, refrigerants, solar cells, fluoropolymers, lithium batteries, metallurgy and other advanced industrial segments.

Few Top Global Clientele

syngenta

DUPONT

ADAMA

SUMITOMO CHEMICAL

Nissei Corporation

42%
Of Consolidated Revenue

28%
Of Consolidated Revenue

30%
Of Consolidated Revenue

& 50+
Other MNC's

Note: The Brand Names mentioned are the property of their respective owners and are used here for identification purpose only

State of the Art **Manufacturing Facilities**

14
Manufacturing Plants*

3,500+
Employees

Equipped with Pilot Plant Facility

Strategically located Near Ports

Certifications

- **Glass-lined, Titanium clad stainless-steel reactors** enabling diverse range of products
- **State-of-the-art infrastructure**, including Continuous flow Silicon Carbide and glass reactors (Corning G1 and G4)
- **World class quality control** system with continuous improvement

Installed Manufacturing Capacity

Specialty Chemicals

2,00,000+ MT
Installed Capacity

- **Anupam Rasayan**
  Surat & Jhagadia, Gujarat
- **Tanfac Industries**
  Cuddalore, Tamil Nadu
- **Jayhawk Fine Chemicals**
  Kansas, U.S

Pharmaceutical Formulation

4,800+ Million Units
Installed Capacity

- **Bliss GVS Pharma**
  - Palghar: 728 Mn Units
  - Vevoor: 3,974 Mn Units
  - Ambernath: 90 Mn Units

**Includes Tanfac , Jayhawk and Bliss GVS Pharma Facilities*

Strong Manufacturing Footprint – India and USA



14+
Countries Exports presence

14 Manufacturing Facilities

- 4 Plants in Sachin, Gujarat
- 2 Plants in Jhagadia, Gujarat
- 1 Plant in Cuddalore, Tamil Nadu
- 6 Plants in Maharashtra
- 1 Plant in Kansas, USA

5 Sales Offices

- India
- Japan
- Switzerland
- USA
- UAE

5 R&D Centers

- Sachin, Gujarat
- Jhagadia, Gujarat
- Cuddalore, Tamil Nadu
- Kansas, USA
- Mumbai, Maharashtra

Map not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Experienced Leadership & Deep Technical Talent Pool



Mr. Anand S Desai
MANAGING DIRECTOR

Over 30 years of experience in chemicals industry associated with company since 1992 & was one of first Directors of company



Mrs. Mona A Desai
VICE-CHAIRPERSON & WHOLE-TIME DIRECTOR

Over 20 years of experience in chemicals industry and associated with the Board since the incorporation of the company



Mr. Gopal Agrawal
CHIEF EXECUTIVE OFFICER

Qualified CA with 25+ yrs. Exp in Corporate Strategy, global M&A and Mgmt Consultancy. Former MD & Head - IB at Edelweiss India



Mr. Ravi Desai
CHIEF OPERATING OFFICER

15+ years of experience in sales; with ARIL for ~12 years



Mr. Amit Khurana
CHIEF FINANCIAL OFFICER

Qualified CA with 14+ yrs. exp in taxes/ accounts; Former Head of Indirect Taxes & Costing of co., with ARIL for ~11years



Ms. Hetvi Vyas
DEPUTY CFO

Qualified CA with 9+ years of experience in finance, accounting, financial reporting and corporate finance.



Dr. Nileshkumar Naik
TECHNICAL HEAD

PhD (Chem), M.Sc. (Organic chemistry); with ARIL since incorporation



Dr. Anuj Thakar
WHOLE TIME DIRECTOR AND R&D HEAD

PhD (Chem), M.Sc. (Organic chemistry); with ARIL for ~18 yrs.



03

Moving up the Value Chain

Expanding Horizon : Backward + Forward Integration

Tanfac Industries Limited

Expansion through Inorganic Acquisition

Acquired 2022

Products	12+
Plant	1
End Users	• Refrigerants • Glass Etching • Solar Cells • Steel Surfacing
Customers	105+

Anupam Rasayan India Limited

Building blocks for growth

1984 onwards

Products	70+
Plants	6
End Users	• Agrochemicals • Pharmaceuticals • Personal Care • Performance Materials
Customers	70+

Jayhawk Fine Chemicals

Global Expansion

2026 onwards

Products	20+
Plant	1
End Users	• Life Sciences • Performance Chemicals
Customers	50+

Bliss GVS Pharma

Advanced Formulation Solutions

2026 onwards


Products	150+
Plant	6
End Users	• Pharmaceuticals • Finished Dosage
Customers	350+

Tanfac - Backward Integration: Fluoro Platform

Company acquired management control in May'22 at a market cap of Rs 5,950 Mn

One of India's largest HF facilities, strengthening in-house HF availability for value-added fluoride derivatives and future downstream expansion

Key Rationale




- **Uninterrupted access** to key raw materials (HF and KF) for fluorination chemistry
- Enable **future expansion** of product series under fluorination chemistry
- **Reduce import dependence**
- **Increased capacities of existing product portfolio** of Tanfac through process improvement & debottlenecking

Strategic Entry into the Refrigerant Gas Market

Key Applications:

- Manufacturing of fluorocarbons & refrigerant gas
- Manufacturing of lithium batteries
- Electronic Grades
- Fluorinated organic products

Revenue Trend (Rs Crores)



Fluorine chemistry has become increasingly integral to new product innovation across agrochemicals, pharmaceuticals, polymers and EV.

Jayhawk – Forward Integration: CDMO Acquisition In US

ANUPAM RASAYAN INDIA LTD.
+
Jayhawk Fine Chemicals

Anupam has acquired Jayhawk Fine Chemicals LLC, U.S.-based specialty chemicals company, at an **enterprise value of ~$134Mn** (total purchase consideration of ~$150Mn includes ~$16Mn of cash & cash equivalents on Jayhawk's balance sheet) **funded through combination of internal accruals, debt and quasi equity**

Key Details

Description:

Manufactures performance materials (~65%) & life / crop science molecules (~35%)

Founded in 1941, located in Kansas, U.S

Financials:

FY26 Revenue: ~$76 Mn

FY26 EBITDA: ~$15 Mn (~19% Margins)

Business Model:

Manufactures high-value specialty intermediates for performance materials and life sciences supported by complex chemistries, specialized manufacturing capabilities and long-standing customer relationships.

Employees:

~140 FTEs with majority of employees in operations

JAYHAWK Fine Chemicals

~800 acres in the U.S.

with <10% utilized, offering strong expansion headroom

Diversifying into ***High-value and less-cyclical segments (Performance Materials)***

Note: Jayhawk has started contributing to the revenue from 27th Feb 2026

Jayhawk – Expanding Footprint In the USA Market

Participation in high value markets
Expands access to fast-growing, innovation-led segments such as semiconductors, automotive / EV, aviation and electronics

US-based platform for CDMO expansion
Offers a strategically valuable platform for Anupam to expand presence in the US and build a global CDMO network (in line with long-term expansion strategy)

Facilitates Sectoral Diversification
Expands the business beyond agrochemicals and pharmaceuticals into high-value, relatively less-cyclical segments such as performance polymers and polyimides.

Complementary tech & integration advantage
Strong synergies via complementary tech – leveraging Jayhawk's high-purity tech with Anupam's backward integration capabilities to enable dual-site production and faster scale-up

Access to strategic customer base
Strengthening access to leading global customers and opens new downstream opportunities





Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

Bliss GVS Pharma - Strategic Acquisition

Anupam Rasayan has acquired a **50.07% controlling stake in Bliss GVS Pharma**, strengthening its presence in the pharmaceutical sector. The acquisition is funded through a combination of a **Rs 300 crore term loan and a Rs 1,450 crore non-controlling and non-voting instrument.**

30% Capacity Utilization

50+ Therapeutic segments


16+ Dosage forms

150+ Brands

1,000+ Employees

80+ Scientists

Global Accreditations



& **25+** Accreditations

Key Details

- Incorporated in 1984.
- Manufactures branded formulations across Anti-malarial, Anti-fungal, Anti-bacterial, Antibiotic, anti-inflammatory, Anti-infective, Anti-diabetic, Cardiovascular, Gastrointestinal, Respiratory, Urology and contraceptive segments.
- Renowned for its flagship anti-malarial WHO endorsed brand (Lonart).
- Long-standing distributor relationships (spanning over 20-25 years).
- Bliss GVS Pharma is the first EU-GMP certified suppositories manufacturer in India.
- 6 Manufacturing facilities in Palghar, Vevoor and Ambernath across Maharashtra.

Signed Strategic agreements in USA and Canada, along with recent USFDA approval to Palghar suppository unit to bring significant revenue potential.

Asterisk Lifesciences Ltd, UK a wholly owned subsidiary of Bliss GVS Pharma, received marketing authorization from the Medicines & Healthcare products Regulatory Agency (MHRA) for Mesalazine 1g Suppositories.

Note: Bliss GVS Pharma has started contributing to the revenue from 28th September 2026

Bliss GVS Pharma – Expansion & Forward Integration

ANUPAM RASAYAN

Bliss GVS

Raw Material & chemistry Development → **KSM & Intermediates** → **Process Development & Scale up** → **Pharmaceutical Formulation** → **Finished Dosage** → **Global Accreditation**

US FDA/ EU GMP

01 **Synergies with Therapeutic Areas:**
Expansion into Cardiovascular, Antidiabetic, Antibiotics, Analgesic & Anti-inflammatory, Anti-Retrovirals, Antifungals, Anti-depressant and Anti-malarial segments

02 **Expansion into CDMO Business:**
Expanding into regulated markets through Vevoor facility which is FDA approved.

03 **Forward Integration:**
End-to-End Vertically integrated Manufacturing to give cost and resource leverage.

04 **Capacity Utilization Ramp Up:**
Significant headroom available to improve capacity utilization, supported by customer engagements, & increasing demand across key business segments

05 **Entering into Regulated Markets:**
Using expertise in North America to expand in regulated markets

06 **High Barrier Segment:**
Strengthening Presence in segments with high entry barriers and differentiated capabilities.

Robust pipeline of 62+ molecules over the next two years, with 48+ molecules catering to regulated markets

Integrated Platform with **Resilient Business Model**

Critical RM control → **Differentiated material platforms** → **High value end markets**

TANFAC	ANUPAM RASAYAN	JAYHAWK Fine Chemicals	Bliss GVS
(HF & KF production)	*(Advanced intermediates)*	*(Synthesis & transformation)*	*(Pharmaceutical Formulation)*
HF	**Fluorinated Intermediates**	**Aromatic Dianhydrides**	**Creams, Ointments & Gels**
KF	**Aromatic Diamines**	**Custom Synthesis**	**Tablets, Capsules & Dry Syrups**
	Non- Fluorinated Intermediates		

- Polymers (Polyimides | Epoxies)
- Pharmaceutical (Finished Dosage Form)
- Electronic Chemicals (Semiconductor materials)
- API / advance pharma intermediates
- Crop Protection Actives / Intermediates
- Battery Chemicals

Global footprint and combined capabilities supporting independent specialty manufacturing platform

Note: HF is Hydrofluoric Acid & KF is Potassium Fluoride

04

Key Strategy & Growth Drivers



Key Growth Drivers



Pharmaceutical & Polymer Expansion

- Building an Integrated Pharmaceutical Platform through the Acquisition of Bliss GVS Pharma.
- Increasing contribution from high growth Polymer business
- Better product mix expected to support margins

Long-Term LOIs & Customer Contracts

- Strong revenue visibility through multi-year LOIs and long-term customer contracts
- Strategic partnerships with global innovators

Strengthening Supply Chain

- Integration in Customer supply Chain
- Acquisition of Tanfac for backward integration
- Forward Integration through Jayhawk acquisition

Sustainable Business Model

- Partner of choice for originators/leading MNC
- Multi pronged strategy leading to high growth

Building a globally diversified specialty chemicals platform through higher-value products, long-term customer relationships and strategic acquisitions.

Strong Order Book: Recent LOI/Contracts Signed

Signing Quarter	Segment	Customer	LOI/Contract	Tenor (Years)	Status	Value (₹ Crores)
Q1FY22	Life Science	Multinational Life Science Company	LOI	5	Commercialized	1,100
Q1FY22	Life Science	Two Multinational Companies	Contract	5	Commercialized	540
Q2FY22	Life Science	European Multinational Company	Contract	5	Commercialized	144
Q3FY22	Life Science	Japanese Multinational Company	Contract	4	Commercialized	135
Q4FY22	Life Science	Multinational Crop Protection Company	LOI	5	Commercialized	700
Q4FY23	Life Science	Japanese Chemical Company	LOI	6	To be commercialized in FY27	984
Q1FY24	Other Specialty Chemical	Japanese Multinational	LOI	7	Commercialized	1,500
Q1FY24	Other Specialty Chemical	American Multinational	LOI	5	To be commercialized in FY27	380
Q1FY24	Life Science	Japanese Chemical Company	LOI	5	To be commercialized in FY28	2,186
Q3FY24	Other Specialty Chemical	Japanese Multinational Chemical Company	LOI	9	Commercialized	507
Q4FY24	Other Specialty Chemical	Japanese Multinational	LOI	7	Commercialized	743
Q4FY25	Other Specialty Chemical	US Multinational Company	LOI	10	Commercialized	1,697
Q4FY25	Other Specialty Chemical	US Multinational Company	Contract	1	Commercialized	108
Q4FY25	Battery Chemical	Elementium	LOI	5	To be commercialized in FY27	3,000
Q4FY25	Other Specialty Chemical	Korean Multinational	LOI	10	To be commercialized in FY27	922
Q1FY27	Other Specialty Chemical	BASEQUEVOLT, S.A	LOI	10	To be commercialized in FY27	2,850
Q2FY27	Other Specialty Chemical	US Speciality Metal Manufacturer	Contract	6	To be commercialized in FY27	CONFIDENTIAL
Total						**17,496**



Company Details:

ANUPAM RASAYAN INDIA LTD.

Anupam Rasayan India Limited
CIN – L24231GJ2003PLC042988
www.anupamrasayan.com

Investor Relations Advisor :

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Mr. Shrikant Sangani / Ms. Shaily Patwa
Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net
Mobile No – 9619595686 / 9819494608
www.sgapl.net

Thank You